The objective of the study was to observe the results of bone marrow flow cytometric (BMFC) typing and pathological immunohistochemical (PI) of lymphoma cell leukemia (LCL), and then provide scientific data for clinical typing of lymph node cell leukemia. The BMFC typing and PI data of 86 patients with LCL admitted to our hospital from January 2018 to January 2022 were retrospectively analyzed to compare the BMFC typing and PI expression, and investigate the diferences in PI results among patients with diferent BMFC typing. There were significant diferences in bone marrow flow cytometry immunogen level between T lymphocyte type and B lymphocyte type (P<0.05). CD3, BCL-2, CD7, TDT and CD34 were the dominant PI typing of T cell type. The expression rate of BCL-2 was 100.00% and that of CD3 was 91.67% (33/36), followed by TDT, CD7 and CD34. CD20, CD79a, BCL-6 and BCL-2 were the dominant PI typing of B-cell type. CD20 had the highest expression rate (100.00%), followed by CD79a and BCL-6. There were significant diferences in PI typing antigen level between T lymphocyte type and B lymphocyte type (P<0.05). Regarding the correlation between the same antigen of BMFC typing and PI typing, only CD3, CD7 and CD20 were correlated (r>0, P<0.05). CD5 exhibited no correlation (P>0.05). BMFC typing and PI antigen typing of LCL are only correlated in terms of CD3, CD7 and CD20 antigens, with complementary efects shown in other antigens. It was concluded that clinical selection should be made by comprehensive consideration of patients' conditions.